Register or Sign in to Save this opportunity, or Send an Inquiry.
Early Stage, CIS Pharma Develops Cellophil® Antibody Drug Conjugates (ADCs) to Upgrade the Arsenal Against Cancer.
CIS Pharma AG, Switzerland Switzerland flag Switzerland
Abstract ID:
CIS Pharma develops Cellophil® Antibody drug conjugates to conquer the limitations of conventional ADCs by increase of cytotoxic payloads even for strong hydrophobic drugs.
Send an Inquiry
RE:
Participants
You
FEATURED
Last Updated Feb 2019
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
CORPORATION

Opportunity Contact